초록 ▼

Liposomal-encapsulated taxane or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer. The liposomal encapsulated paclitaxel allows for administration to a patient, particularly a human patient, in less tha

Liposomal-encapsulated taxane or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer. The liposomal encapsulated paclitaxel allows for administration to a patient, particularly a human patient, in less than one hour without substantial toxicity.

대표청구항 ▼

I claim: 1. A method of administering a taxane to a human patient in need of treatment with a taxane comprising administering a pharmaceutical composition to said human patient over a period between about 45 minutes to about one hour in an amount from about 135 mg/m2 to about 300 mg/m2 wherein said

I claim: 1. A method of administering a taxane to a human patient in need of treatment with a taxane comprising administering a pharmaceutical composition to said human patient over a period between about 45 minutes to about one hour in an amount from about 135 mg/m2 to about 300 mg/m2 wherein said pharmaceutical composition is a liposomal encapsulated taxane. 2. The method of claim 1, wherein said taxane is selected from the group consisting of paclitaxel, 7-epipaclitaxel, t-acetyl paclitaxel, 10-desacetyl-paclitaxel, 10-desacetyl-7-epipaclitaxel, 7-xylosylpaclitaxel, 10-desacetyl-7-glutarylpaclitaxel, 7-N,N-dimethylglycylpaclitaxel, 7-L-alanylpaclitaxel, taxotere, and mixtures thereof. 3. The method of claim 1, wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient. 4. The method of claim 1, wherein said pharmaceutical composition further comprises cardiolipin. 5. The method of claim 4, wherein said cardiolipin is selected from the group consisting of natural cardiolipin and synthetic cardiolipin. 6. The method of claim 1, wherein said amount of said taxane is about 135 mg/m2. 7. The method of claim 1, wherein said amount of said taxane is about 175 mg/m2. 8. The method of claim 1, wherein said amount of said taxane is about 250 mg/m2. 9. The method of claim 1, wherein said amount of said taxane is about 300 mg/m2. 10. The method of claim 1, wherein said patient is suffering from ovarian cancer, breast cancer, lung cancer, lymphoma or colon cancer. 11. The method of claim 1, wherein said liposomal encapsulated taxane is administered by intravenous infusion. 12. The method of claim 1, wherein said administration of said liposomal encapsulated taxane is repeated at least once every 21 days. 13. The method of claim 1, wherein said administration of said liposome encapsulated taxane is administered intraperitoneally to patients suffering from cancer. 14. The method of claim 13, wherein said administration of said liposome encapsulated taxane is administered intraperitoneally to patients suffering from colon cancer. 15. A method of treating a human having cancer with a taxane comprising administering a large quantity of a liposomal taxane to said human between about 45 minutes to about one hour without inducing a substantial toxic reaction. 16. The method of claim 15 in which the liposomal taxane is administered intravenously. 17. The method of claim 15 in which the liposomal taxane is administered as a single agent without pretreatment by steroids, antihistamines, H2-antagonists or antihypersensitivity agents. 18. The method of claim 15 in which substantial nonhematological toxicity is not induced. 19. The method of claim 15 in which substantial anaphylaxis is not induced. 20. The method of claim 15 in which the large quantity of the liposomal taxane ranges from about 135 mg/m2 to 300 mg/m2. 21. The method of claim 15 in which the large quantity of the liposomal taxane ranges from about 175 mg/m2 to 300 mg/m2. 22. The method of claim 15 in which the large quantity of the liposomal taxane ranges from about 175 mg/m2 to 250 mg/m2. 23. The method of claim 15 in which the large quantity of the liposomal taxane is about 250 mg/m2. 24. The method of claim 15, in which the liposomal taxane is rapidly administered between about 45 minutes and about one hour. 25. The method of claim 15, in which the liposomal taxane is rapidly administered in about 45 minutes. 26. The method of claim 15 further comprising repeating the step of administering a large quantity of a liposomal taxane to a human between about 45 minutes to about one hour without inducing a substantial toxic reaction. 27. The method of claim 26 wherein the repeating step occurs in 21 days. 28. A method of administering a taxane to a human patient in need of treatment with taxane comprising administering a pharmaceutical composition to said human patient in an amount of at least about 300 mg/m2 over a period of between about 45 minutes to about one hour wherein said pharmaceutical composition is a liposomal encapsulated taxane. 29. A method of treating a human with a taxane comprising administering a liposomal taxane ranging from about 75 mg/m2 to about 300 mg/m2 to a human between about 45 minutes to about one hour without inducing a substantial toxic reaction. 30. The method of claim 29 in which the liposomal taxane is administered intravenously. 31. The method of claim 29 in which the liposomal taxane is administered as a single agent without pretreatment by steroids, antihistamines, H2-antagonists or antihypersensitivity agents. 32. The method of claim 29 in which substantial nonhematological toxicity is not induced. 33. The method of claim 29 in which substantial anaphylaxis is not induced. 34. The method of claim 29 in which the large quantity of the liposomal taxane ranges from about 90 to 300 mg/m2. 35. The method of claim 29 in which the large quantity of the liposomal taxane ranges from about 135 to 300 mg/m2. 36. The method of claim 29 in which the large quantity of the liposomal taxane ranges from about 175 to 300 mg/m2. 37. The method of claim 29 in which the large quantity of the liposomal taxane ranges from 175 to 300 mg/m2. 38. The method of claim 29 in which the large quantity of the liposomal taxane is about 250 mg/m2. 39. The method of claim 29, in which the liposomal taxane is rapidly administered in about 45 minutes to about one hour. 40. The method of claim 29, in which the liposomal taxane is rapidly administered in about 45 minutes. 41. The method of claim 29, further comprising repeating the step of administering a liposomal taxane ranging from about 75 mg/m2 to about 300 mg/m2 to a human between about 45 minutes to about one hour without inducing substantial hematological or nonhematological toxicity. 42. The method of claim 41, wherein the repeating step occurs in 21 days.